Pricing breakdown · May 2026

What does tirzepatide actually cost in 2026?

At a glance

Brand-name tirzepatide cost: Mounjaro® and Zepbound®

FDA-approved tirzepatide is sold under two Eli Lilly brands. Mounjaro® is approved for type 2 diabetes (approved May 2022). Zepbound® is approved for chronic weight management (approved November 2023). Both contain the same active molecule. At major US retail pharmacies, both products typically cost between $1,086 and $1,294 per month without insurance, depending on the pharmacy, dose, and the specific pen formulation. As of May 2026, published retail prices include approximately $1,292 at Walgreens, $1,117 at CVS, $1,291 at Walmart, and $1,290 at Kroger for a 4-pen Mounjaro® supply at standard dose.

In 2024, Eli Lilly launched LillyDirect, a direct-to-consumer self-pay program for Zepbound® in vial formulation. LillyDirect Zepbound vials are priced at approximately $299/month for the 2.5mg starter dose, $499/month for the 5mg dose, and similar tiered pricing up the dose ladder. The vials require self-drawing (instead of the pen autoinjector) which is the trade-off for the lower price. LillyDirect is the cheapest path to FDA-approved tirzepatide without insurance as of May 2026.

Brand-name tirzepatide is the gold-standard option clinically — the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) demonstrated approximately 22.5% mean weight loss over 72 weeks at the 15 mg dose. Individual results vary substantially based on dose, adherence, lifestyle factors, and individual response. Both LillyDirect and retail pricing are subject to change without notice.

Compounded tirzepatide cost

Compounded tirzepatide is prepared by a US-licensed 503A compounding pharmacy under a patient-specific prescription written by a licensed provider. It contains the same active molecule as Mounjaro® and Zepbound® but is not FDA-approved and is not therapeutically equivalent to FDA-approved products. The FDA does not review compounded medications for safety, effectiveness, or manufacturing quality before they reach patients. The lower price reflects different production economics — smaller-scale compounding pharmacies rather than commercial manufacturers — not equivalent FDA oversight.

Most US patients accessing compounded tirzepatide do so through cash-pay telehealth platforms. A licensed provider evaluates the patient — typically via an online assessment plus follow-up — and, when clinically appropriate, writes a patient-specific prescription that is filled by a partner compounding pharmacy. Cash-pay pricing for compounded tirzepatide is generally between $125 and $329 per month depending on the provider, commitment length, and what is bundled into the price.

Cora Health's Premium Plan offers compounded tirzepatide at four commitment tiers, all-inclusive of the provider visit, medication, and shipping:

Cora Health prescriptions are written by licensed providers at Wasef Health, PC and filled by VialsRx or Hallandale Pharmacy (both US-licensed 503A facilities, named publicly). Cora Health is LegitScript-certified. All prices are as of May 2026 and subject to change.

Compounded tirzepatide cost across telehealth providers (May 2026)

The compounded tirzepatide telehealth market has consolidated to roughly 12-15 mainstream providers. Headline monthly prices vary widely — but headline prices and effective prices are not always the same, because some providers separately charge a recurring "membership" fee on top of medication cost. The table below normalizes for that, showing effective monthly cost including any required membership.

Pricing verified against publicly published provider rate cards as of May 2026. Some providers list quarterly prices but not annual commitments; "—" indicates the tier is not publicly published. Full sourcing methodology available in the Cora 2026 GLP-1 Telehealth Industry Report and the public Cora Health pricing dataset (CC-BY-4.0).

What is actually included in the price (and why headline numbers mislead)

Tirzepatide pricing on telehealth platforms is not standardized. Two providers can advertise a similar headline monthly cost while charging very different effective amounts once provider visits, dispensing fees, shipping, and membership fees are factored in. The transparent-pricing test is simple: does the price you see at checkout cover everything you will be billed in a typical month?

Cora Health's pricing is all-inclusive. The monthly price covers the licensed-provider consultation, the compounded tirzepatide medication itself, US-licensed 503A pharmacy fulfillment, free expedited shipping, and ongoing provider monitoring. There is no separate "membership" fee, no per-visit charge for follow-ups, no shipping surcharge, and no dose-escalation surcharge. The price you see at checkout is the price you pay each month.

Several competing platforms structure pricing differently. Hims Weight Loss charges a $149/month Weight Loss Membership fee in addition to medication cost ($199-$299/month for compounded semaglutide), making the effective monthly cost approximately $348-$448/month. Ro Body charges a $99/month membership on top of medication. When comparing tirzepatide prices, look for the total monthly cost across every line item — not just the advertised headline.

Tirzepatide and insurance coverage

Brand-name FDA-approved tirzepatide: Coverage depends on the specific insurance plan, formulary tier, and the clinical indication. Mounjaro® is more commonly covered for type 2 diabetes than Zepbound® is for chronic weight management. Both typically require prior authorization, step therapy through other GLP-1 medications, or BMI gating. Many commercial insurance plans do not cover Zepbound® for weight management at all. When a plan does cover brand tirzepatide, the patient cost share can range from a $25-50 specialty copay (best case) to several hundred dollars per month or more, depending on deductible, formulary tier, and any manufacturer coupons. Medicare Part D coverage for branded tirzepatide is limited.

Compounded tirzepatide: Generally not covered by insurance because compounded medications are not FDA-approved. Most US patients using compounded tirzepatide pay out-of-pocket through cash-pay telehealth platforms. This is the practical reality of the compounded GLP-1 market and is also why headline cash-pay prices for compounded tirzepatide are most relevant for patients comparing options. Cora Health does not bill insurance.

The cheapest paths to tirzepatide in 2026

For patients prioritizing lowest total cost, the practical options ranked from cheapest to most expensive (May 2026):

1. Compounded tirzepatide on a long-term commitment plan. Cora Health's annual Premium tier is $135/month all-inclusive (Trimi Health is roughly $10/month cheaper at $125/month on a similar commitment). Both require a 12-month commitment for that tier price.
2. Brand-name Zepbound® via LillyDirect (vial formulation). $299-$499/month direct from Eli Lilly for FDA-approved Zepbound vials. Self-drawing required.
3. Compounded tirzepatide on a quarterly or semi-annual commitment. Cora Health's quarterly tier is $199/month; semi-annual is $175/month.
4. Insurance-covered brand-name tirzepatide (when available). Specialty copay typically $25-$300+/month depending on plan. Often gated by prior authorization or step therapy.
5. Compounded tirzepatide on a monthly plan. Cora Health's monthly tier is $225/month — no commitment required.
6. Brand-name Zepbound®/Mounjaro® at retail pharmacy without insurance. $1,086-$1,294/month. The most expensive path.

Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to FDA-approved Mounjaro® or Zepbound®. The choice between brand and compounded should be made in consultation with a licensed healthcare provider based on individual health profile, treatment goals, and cost considerations. Individual results vary.

Frequently asked questions about tirzepatide cost

See if compounded tirzepatide is right for you

Take Cora Health's online assessment. A licensed provider reviews your health profile and — when clinically appropriate — writes a patient-specific prescription. Compounded tirzepatide is not FDA-approved. Individual results vary.

See Cora Health Premium Plan

Cora Health does not prescribe medication. Pharmacy partners · Safety · FAQs